Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 0.86 |
| ▸ | ITK | Q08881 | 5/20 | 0.81 |
| ▸ | EGFR | P00533 | 4/20 | 0.74 |
| ▸ | TEC | P42680 | 3/20 | 0.74 |
| ▸ | BMX | P51813 | 3/20 | 0.74 |
| ▸ | TXK | P42681 | 2/20 | 0.74 |
| ▸ | LYN | P07948 | 2/20 | 0.74 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.74 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.74 |
| ▸ | LATS1 | O95835 | 1/20 | 0.74 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.74 |
| ▸ | ABL1 | P00519 | 1/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | FYN | P06241 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | CSF1R | P07333 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21338961 | 0.94 | BTK (1.00) | BTKBLKITKEGFRTEC | |
| SCHEMBL21330632 | 0.93 | BTK (1.00) | BTKBLKITKEGFRTEC | |
| SCHEMBL20177279 | 0.93 | BTK (1.00) | BTKBLKITKEGFRTEC | |
| SCHEMBL21338838 | 0.93 | BTK (0.91) | BTKBLKITKEGFRTEC | |
| SCHEMBL21330630 | 0.93 | BTK (0.91) | BTKBLKITKEGFRTEC | |
| SCHEMBL20177281 | 0.93 | BTK (0.91) | BTKBLKITKEGFRTEC | |
| SCHEMBL21330634 | 0.91 | BTK (1.00) | BTKBLKITKEGFRTEC | |
| SCHEMBL20177221 | 0.89 | BTK (1.00) | BTKBLKITKEGFR | |
| SCHEMBL19763388 | 0.89 | EGFR (0.85) | BTKBLKITKEGFRTEC | |
| SCHEMBL20177256 | 0.88 | BTK (1.00) | BTKBLKITKEGFRTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| CN-108069974-B | Selective Bruton tyrosine kinase inhibitor and application thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) | 2019-12-10 | — | — | CN | disclosed |
| EP-3543239-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Hertz Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
| WO-2018090792-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | 杭州和正医药有限公司 | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | BTK, BMX, KCNK10 | BTK 1/4885BLK 12/4885ITK 56/4885 |
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | BTK, SYK, LYN | BTK 1/4885BLK 35/4885ITK 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.